Roundview Capital LLC Sells 10,425 Shares of Pfizer Inc. (NYSE:PFE)

Roundview Capital LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 26.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 29,269 shares of the biopharmaceutical company's stock after selling 10,425 shares during the quarter. Roundview Capital LLC's holdings in Pfizer were worth $742,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Clarity Asset Management Inc. purchased a new position in Pfizer during the fourth quarter valued at $27,000. Gould Capital LLC raised its position in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. North Capital Inc. purchased a new position in shares of Pfizer in the 1st quarter worth about $28,000. Bernard Wealth Management Corp. purchased a new position in shares of Pfizer in the 4th quarter worth about $30,000. Finally, Horizon Financial Services LLC purchased a new position in shares of Pfizer in the 1st quarter worth about $35,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 0.1%

NYSE:PFE traded up $0.01 during midday trading on Thursday, hitting $25.37. 25,643,723 shares of the company traded hands, compared to its average volume of 38,513,248. The firm's fifty day moving average is $24.26 and its 200-day moving average is $24.70. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The firm has a market capitalization of $144.25 billion, a P/E ratio of 18.39, a P/E/G ratio of 0.92 and a beta of 0.58. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer's quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.82 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.78%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analyst Ratings Changes

A number of brokerages have weighed in on PFE. Leerink Partners decreased their target price on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research report on Wednesday, April 30th. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price for the company. BMO Capital Markets cut their price target on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Citigroup boosted their price target on Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, The Goldman Sachs Group boosted their price target on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.